Table 2 Incidence of endoscopic findings and adverse events in the one-year treatment.

From: Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial

 

Intervention group (n = 57)

Control group (n = 63)

p value

UGIH

0

2

0.497a

Peptic lesions

26

31

0.694a

      Ulcers

1

2

1.000a

      Esophagitis

8

3

0.183a

      Erosive gastritis

12

17

0.633b

      Duodenitis

5

9

0.362a

Severe PHG

3

1

0.348a

EVBL

4

10

0.206a

Dyspeptic symptoms

11

4

0.063a

Musculoskeletal pain

8

1

0.047b

      Arthralgia

4

1

0.343a

      Myalgia

4

0

0.100a

  1. aFisher exact test. bChi-square test. UGIH: upper gastrointestinal hemorrhage; PHG: portal hypertensive gastropathy; EVBL: endoscopic variceal band ligation.
Back to article page